Your session is about to expire
← Back to Search
Study Summary
This trial is testing a new drug for safety and how well it is tolerated. Blood tests will be performed to check how much of the drug gets into the bloodstream and how long it takes the body to eliminate it. The trial will last up to 28 weeks and include 19 visits.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You have long-term health problems with your heart, liver, or kidneys.You have a history of severe allergies or have had serious reactions to multiple drugs or treatments in the past.You have a body mass index (BMI) in the range of 18.
- Group 1: LY3841136 (Part B)
- Group 2: LY3841136 (Part A)
- Group 3: Placebo (Part A)
- Group 4: Placebo (Part B)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What type of individuals would be suitable candidates for this medical experiment?
"This clinical trial is recruiting 160 individuals aged 18-65 with obesity. Notably, male patients must consent to using reliable forms of contraception, female applicants must be infertile and all participants should have maintained a stable weight for the last three months and possess a BMI between 18.5 - 32 kg/m² in Part A or 27 – 40kg/m² in Part B."
What is the current size of this medical experiment's participant pool?
"To complete this trial, 160 individuals that meet the criteria need to sign up. Patient recruitment is available across locations like LabCorp CRU, Inc in Daytona Beach and Covance Dallas in Texas."
Has the Food and Drug Administration given its stamp of approval to LY3841136?
"The safety of LY3841136 is rated as 1 on our internal scale due to the fact that this study only has initial evidence regarding its efficacy and safety."
Is this trial actively seeking participants?
"Affirmative. The information posted on clinicaltrials.gov conveys that recruitment for this trial is still ongoing, having first been announced back in March 30th 2022 and being updated as recently as November 22nd 2022. 160 test subjects are required across 3 distinct sites for the study to be successful."
Does this research have an age cut-off for participant inclusion?
"To be accepted into this trial, applicants must fall between the ages of 18 and 65. For those younger than 18 or older seniors aged 65+, there are 272 studies available for minors and 1059 clinical trials tailored to elders."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
What questions have other patients asked about this trial?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger